Prometheus Biosciences Inc (RXDX) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Mar 31 2023 to Mar 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Prometheus Biosciences Inc   (NASDAQ: RXDX)

Prometheus Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Prometheus Biosciences Inc in the third quarter 2023?
Prometheus Biosciences Inc recorded a cumulative net loss of $-151 million during 12 months ending in the third quarter 2023, resulting in a negative return on equity (ROE) of -33.5%.

Within the Major Pharmaceutical Preparations industry 138 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3100, from total ROE ranking in the fourth quarter 2022 at 3420.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2023)
III. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter
Y / Y Equity Change 237.46 % 187.46 % -11.28 % -32.08 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -151 -142 -133 -123 -108
Return On Equity (TTM) -33.5 % -43.38 % -61.37 % -54.91 % -43.92 %
RXDX's Total Ranking # 3100 # 3420 # 0 # 0 # 0
Equity (TTM) in Millions 698 676 233 192 207
Seq. Equity Change 3.2 % 190.7 % 21.22 % -7.2 % -12.09 %
Seq. Net Income Change - - - - -

Back to RXDX Management Effectiveness >> RXDX's 5 Years Annual ROE >> Compare RXDX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 139
Sector # 351
Overall # 3100

Return On Equity Statistics
High Average Low
-33.41 %
-64.63 %
-119.44 %
(Dec 31 2021)   (Sep 30 2017)





RXDX Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Equity in Millions 676 235 95 136 56
Y / Y Equity Change 187.46 % 148.13 % -30.31 % 143.06 % 33.89 %
Net Income in Millions -142 -90 -104 -92 -40
Y / Y Net Income Change - - - - -
Return On Equity -20.97 % -38.36 % -109.36 % -67.99 % -71.48 %

Back to RXDX Management Effectiveness >> RXDX's 5 Years Annual ROE >> Compare RXDX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RXDX's' Return on Equity at Yahoo Finance
RXDX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RXDX's Competitors
Subscribers only: Roe for Prometheus Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for RXDX's Customers




Companies with similar Return On Equity at Mar 31 2023, within Healthcare Sector ROE

Date modified: 2026-09-26T07:39:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.